Montelukast Viatris (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related mediators from binding. This inhibition reduces bronchoconstriction, mucus production, and inflammatory cell activity, helping to keep the airways open and less reactive.

The specific dose of Montelukast Viatris is determined by the prescribing healthcare professional based on the patient’s age, condition, and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Montelukast in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals. Patients should discuss any concerns with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients with allergic components or exercise‑related symptoms, but it is generally used as add‑on therapy rather than a sole replacement for inhaled steroids.

Montelukast Viatris should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and excessive heat to maintain stability.

Montelukast Viatris is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, and the exact timing (e.g., morning or evening) is directed by the prescribing clinician.

Serious risks include rare but severe allergic reactions such as angioedema, skin conditions like Stevens‑Johnson syndrome, eosinophilic granulomatosis with polyangiitis, and neuropsychiatric events including depression or suicidal thoughts. Patients should seek immediate medical attention if any of these occur.

Montelukast Viatris should be avoided in individuals with known hypersensitivity to Montelukast or any component of the formulation. Caution is also advised for patients with severe hepatic impairment or those who have experienced serious neuropsychiatric reactions to leukotriene modifiers.